Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Conditions
Keywords
Lung
Brief summary
This study investigates the changes in positron emission tomography (PET)/computed tomography (CT) imaging scans during chemoimmunotherapy and radiation therapy treatment in patients with stage IV non-small cell lung cancer. Analyzing changes in PET/CT imaging scans may help doctors assess and predict patterns of cancer response to chemoimmunotherapy and radiation therapy.
Detailed description
Patients undergo PET/CT scan within 4 weeks before starting standard of care chemoimmunotherapy and a second PET/CT scan within 5 days of the second chemoimmunotherapy cycle. Patients receiving standard of care radiation treatment undergo additional PET/CT scans within 4 weeks prior to radiation treatment and 1 month post-radiation treatment. Additionally, patients undergo blood sample collection on study. Patients may also undergo magnetic resonance imaging (MRI) as clinically indicated throughout the study.
Interventions
PROCEDUREPositron Emission Tomography
Undergo PET/CT scan
PROCEDUREComputed Tomography
Undergo PET/CT scan
DRUGChemotherapy
Receive standard of care chemotherapy
BIOLOGICALImmunotherapy
Receive standard of care immunotherapy
RADIATIONRadiation Therapy
Undergo standard of care radiation therapy
PROCEDUREBiospecimen Collection
Undergo blood sample collection
PROCEDUREMagnetic Resonance Imaging
Undergo MRI
Sponsors
University of Washington
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically-confirmed or cytologically-confirmed metastatic NSCLC in patients who have not received chemotherapy or immunotherapy for their advanced disease (stage IV or recurrent, using the American Joint Committee on Cancer \[AJCC\]/Union for International Cancer Control \[UICC\] 8th edition for staging) * Evidence of stage IV disease on imaging by CT, PET/CT, or magnetic resonance imaging (MRI) * Plan to treat with a platinum doublet with a PD1 or PDL1 inhibitor * Adjuvant chemotherapy or concurrent chemoradiation for early stage disease does not count as prior therapy unless subject progressed within 6 months of completion of regimen. * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, at treating physician's discretion * Subjects must be ≥ 18 years of age * Patients with known activating mutations in EGFR, BRAF or known translocation in ALK or ROS-1 are eligible provided they have progressed on or were intolerant to Food and Drug Administration (FDA) approved targeted therapy * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 * Creatinine =\< 2 mg/dL or creatinine clearance \> 50 mL/min * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 5x institutional upper limit of normal * Total bilirubin =\< 1.5 mg/dL * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L (\>= 1500 per mm\^3) * Platelet count \>= 100 x 10\^9/L (\>=100,000 per mm\^3) * Capability to understand and comply with the protocol requirements and signed informed consent documents
Exclusion criteria
* Any known additional malignancy (with exception of non-melanoma skin cancer, in-situ breast cancer, low risk prostate cancer, or a malignancy diagnosed \>= 3 years prior to the current NSCLC diagnosis and with no evidence of requiring active treatment) * Had prior treatment with an anti-PD-1, or PD-L1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms * Has any serious or uncontrolled active infection that could create false positives on a PET/CT scan, in the opinion of the treating investigator * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator * Has an active autoimmune disease currently requiring systemic treatment (e.g. disease modifying agents, corticosteroids or immunosuppressive drugs) \*\*Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment * Has known, active, and symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis * Patients with stable or previously treated brain metastases are eligible as long as they are not receiving more than 10 mg of prednisone, or equivalent, per day
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Actuarial disease progression rate | At 1 year | Will be compared between high-risk and low-risk subgroups of patients based on positron emission tomography/computed tomography imaging biomarker changes using a two-sample proportionality test. |
Countries
United States
Contacts
CONTACTStephen R. Bowen, PhD
PRINCIPAL_INVESTIGATORLei Deng, MD
Fred Hutch/University of Washington Cancer Consortium
Outcome results
None listed